东诚药业股价小幅回落 半年报显示原料药营收下滑

Group 1 - The stock price of Dongcheng Pharmaceutical is reported at 18.10 yuan, down 1.04% from the previous trading day, with a trading volume of 4.92 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical raw materials, nuclear medicine, and formulations, with products including heparin sodium raw materials and diagnostic drugs for nuclear medicine [1] - The latest semi-annual report shows a revenue of 1.384 billion yuan for the first half of the year, a year-on-year decrease of 2.60%, and a net profit attributable to shareholders of 89 million yuan, down 20.70% year-on-year [1] Group 2 - Revenue from the raw material drug business is 611 million yuan, a year-on-year decline of 7.02%, while the nuclear medicine segment revenue is 503 million yuan, showing a year-on-year growth of 0.78% [1] - On the capital flow side, Dongcheng Pharmaceutical experienced a net outflow of 3.637 million yuan in main funds on the day, with a cumulative net outflow of 71.2004 million yuan over the past five days [2]